BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31200359)

  • 1. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Gbolahan O; Hashemi-Sadraei N; O'Neil B
    J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
    Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
    Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
    Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
    Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
    Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI
    J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
    Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
    Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
    ;
    J Hepatol; 2023 Jul; 79(1):181-208. PubMed ID: 37084797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adoptive T-cell immunotherapy on immune cell profiles and prognosis of patients with unresectable or recurrent cholangiocarcinoma.
    Kida A; Mizukoshi E; Kitahara M; Miyashita T; Goto S; Kamigaki T; Takimoto R; Asai J; Kakinoki K; Urabe T; Tomita K; Kaneko S
    Int J Cancer; 2024 Feb; 154(4):738-747. PubMed ID: 37676069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
    Sucre S; Bullock A; Peters ML
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
    Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
    Cancer Lett; 2024 Jul; 594():216992. PubMed ID: 38797231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
    Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
    Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Clinical Use of Molecular Profiling of Intrahepatic Cholangiocarcinoma in a Comprehensive Multidisciplinary Clinic.
    Purchla J; Ghabi EM; Burns WR; Lafaro KJ; Burkhart RA; Cameron JL; Yarchoan M; Shubert CR; Baretti M; He J
    J Am Coll Surg; 2024 Apr; 238(4):532-540. PubMed ID: 38189646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
    Tran E; Turcotte S; Gros A; Robbins PF; Lu YC; Dudley ME; Wunderlich JR; Somerville RP; Hogan K; Hinrichs CS; Parkhurst MR; Yang JC; Rosenberg SA
    Science; 2014 May; 344(6184):641-5. PubMed ID: 24812403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to incorporate new agents into precise medicine for cholangiocarcinoma?
    Li Y; Kang J; Zhang X
    Am J Cancer Res; 2024; 14(5):2570-2583. PubMed ID: 38859865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
    Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J
    JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
    Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
    Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.
    Lee SH; Lee HS; Lee SH; Woo SM; Kim DU; Bang S
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.